Open AccessClinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones
Author(s) -
Maria Rosalia Pasca,
Giulia Degiacomi,
Ana Ribeiro,
Francesca Zara,
P. De Mori,
Béate Heym,
Maurizio Mirrione,
Roberto Brerra,
Laura Pagani,
Leopoldo Paolo Pucillo,
Panajota Troupioti,
Vadim Makarov,
Stewart T. Cole,
Giovanna Riccardi
Publication year - 2010
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01676-09
Subject(s) - mycobacterium tuberculosis , tuberculosis , microbiology and biotechnology , medicine , antibiotics , drug resistance , genotype , virology , biology , gene , genetics , pathology
The new antitubercular drug candidate 2-[2-S -methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (BTZ043) targets the DprE1 (Rv3790) subunit of the enzyme decaprenylphosphoryl-β-d -ribose 2′-epimerase. To monitor the potential development of benzothiazinone (BTZ) resistance, a total of 240 sensitive and multidrug-resistantMycobacterium tuberculosis clinical isolates from four European hospitals were surveyed for the presence of mutations in thedprE1 gene and for BTZ susceptibility. All 240 strains were susceptible, thus establishing the baseline prior to the introduction of BTZ043 in clinical trials.